ReviewsRenin inhibition with aliskiren: where are we now, and where are we going?Azizi, Michela; Webb, Randyb; Nussberger, Juergc; Hollenberg, Norman KdAuthor Information aClinical Investigation Center 9201, Hospital European Georges Pompidou, Paris, France bDepartment of Cardiovascular Research, Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA cDivision of Hypertension and Vascular Medicine, Centre Hospitalier, Universitaire Vaudois, Lausanne, Switzerland dDepartments of Medicine and Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA Received 16 August, 2004 Revised 28 September, 2005 Accepted 25 October, 2005 Correspondence and requests for reprints to Norman K. Hollenberg, MD, PhD, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA Tel: +1 (617) 732 6682; fax: +1 (617) 232-2869; e-mail: [email protected] Sponsorship: This work was sponsored by Novartis Pharmaceuticals. Journal of Hypertension: February 2006 - Volume 24 - Issue 2 - p 243-256 doi: 10.1097/01.hjh.0000202812.72341.99 Buy Metrics Abstract With the development of aliskiren, blockade of the renin–angiotensin–aldosterone system (RAAS) at the level of the interaction of renin with a substrate has become a clinical reality. This review covers the specific features of the first agent likely to achieve widespread clinical exposure, aliskiren. The potential of renin inhibition must be viewed in the context of the remarkable efficacy of both angiotensin-converting enzyme (ACE) inhibition and angiotensin receptor blockers (ARBs). The implications of blockade of the renin system at its rate-limiting step are reviewed, with the therapeutic implications for both the renin inhibitor employed alone or the renin inhibitor combined with an ACE inhibitor or ARB. The relevant and necessary studies are ongoing. © 2006 Lippincott Williams & Wilkins, Inc.